dabigatran etexilate + BI 1358894

**Dabigatran etexilate + BI 1358894** is a combination of two small molecule drugs. - **Dabigatran etexilate** is an oral anticoagulant prodrug that inhibits thrombin (factor IIa), reducing the formation of fibrin clots. It is used primarily to decrease the risk of stroke and thromboembolism in patients with non-valvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and for prophylaxis in patients undergoing hip or knee replacement surgery[1][3][7][10]. - **BI 1358894** is a small molecule inhibitor of TRPC4/5 ion channels, under investigational development for neuropsychiatric disorders such as borderline personality disorder (BPD) and depression[2][5][6][8]. This combination is not an approved therapy and is primarily found together in clinical pharmacology studies, possibly to assess drug-drug interactions or pharmacodynamic/pharmacokinetic safety in healthy subjects[4]. There is no evidence of combined efficacy in a therapeutic context for any disease.

Brand names

Pradaxa

Other names

dabigatran etexilateBI 1358894BI1358894BI-1358894